Clinical Trial Update: Combination of Toripalimab and JS004 Therapy for ccRCC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of toripalimab and JS004 therapy for clear cell renal cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• JS004 (JS004)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Fudan University | Conditions: Clear Cell Renal Cell Carcinoma | Phase 2 | Status: RECRUITING